What 8 Analyst Ratings Have To Say About Inari Medical
Portfolio Pulse from Benzinga Insights
Inari Medical (NASDAQ:NARI) has received mixed analyst ratings over the past quarter, with 8 analysts offering opinions ranging from bullish to indifferent. The average 12-month price target for NARI has been adjusted to $66.75, down 8.06% from the previous $72.60. Analyst actions include maintaining, lowering, and announcing buy ratings with price targets ranging from $52.00 to $75.00. Inari Medical, a medical device company, has shown a revenue growth of 22.57% as of December 31, 2023, but lags behind industry peers. The company's net margin and ROE outperform industry averages, indicating strong profitability and financial health.
April 12, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Inari Medical has seen a diverse range of analyst ratings, with a revised average price target suggesting a cautious outlook. Despite this, the company's solid revenue growth and strong financial metrics indicate underlying strength.
The mixed analyst ratings and the decrease in the average price target could introduce short-term volatility in NARI's stock price. However, the company's strong revenue growth and financial health metrics, such as net margin and ROE, provide a solid foundation that may mitigate negative impacts and suggest potential for resilience or growth in the medium to long term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100